drugset
Drugs / PF-04383119
last change Mar 2021 re-read 3 minutes ago

PF-04383119

also known as RN624 · tanezumab

Monoclonal antibody

Developed for
interstitial cystitis · osteoarthritis, knee
Investigated by
Pfizer

Trials 2

today NCT00601484 · Ph 2 NCT00584870 · Ph 2
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 22 trials · 1 met primary
Phase 2 NCT00601484 Mar 2008 → Apr 2009 interstitial cystitis Pfizer Completed No outcome recorded
Phase 2 NCT00584870 Jul 2007 → Sep 2008 — Pfizer Completed Met primary
Comparator or background therapy1 trial
Phase 2 NCT00669409 Comparator Jun 2008 → Dec 2009 osteoarthritis, knee Pfizer Completed No outcome recorded

Press releases naming this drug 9 releases

DateIssuerRelease
2021-03-25 Pfizer Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain pfizer.com ↗
2020-03-02 Pfizer U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis pfizer.com ↗
2019-04-18 Pfizer Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis pfizer.com ↗
2019-02-19 Pfizer Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain pfizer.com ↗
2019-01-29 Pfizer Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain pfizer.com ↗
2018-10-23 Pfizer Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients pfizer.com ↗
2018-07-18 Pfizer Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain pfizer.com ↗
2017-06-13 Pfizer Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab pfizer.com ↗
2015-03-23 Pfizer Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab pfizer.com ↗

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as PF-04383119 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00601484 ↗
2

NCT00669409 ↗

NCT00584870 ↗
Known as RN624 “PF-04383119 (RN624)” NCT00584870 ↗
Known as tanezumab “PF-04383119 (tanezumab)” NCT00669409 ↗
Action Inhibit “a humanized monoclonal antibody that inhibits nerve growth factor” PMID 22004765 ↗ Oct 2011
Modality Monoclonal antibody “a humanized monoclonal antibody” PMID 22004765 ↗ Oct 2011
Route Intravenous “Single IV infusion of 200 micrograms/kg RN624 on Day 1” NCT00584870 ↗